Source-grounded facts extracted from ACTUATE THERAPEUTICS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
ACTUATE THERAPEUTICS, INC. shareholders approved Ratification of the appointment of Crowe LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-05-21 meeting.
“ratified the appointment of Crowe LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026”
ACTUATE THERAPEUTICS, INC. shareholders approved Election of two Class II director nominees at the 2026-05-21 meeting.
“elected each of the two Class II director nominees listed below to the Company's Board of Directors, each to serve for a three-year term until the 2029 Annual Meeting of Stockholders, and until their respective successors are duly elected and qualified”
Martin H. Huber was appointed as Class III Director at ACTUATE THERAPEUTICS, INC..
“On May 1, 2026, the Board of Directors ("Board") of Actuate Therapeutics, Inc. (the "Company"), upon the recommendation of the Nominating and Corporate Governance Committee, appointed Martin H. Huber, MD, to the Board.”
ACTUATE THERAPEUTICS, INC. entered into At the Market Issuance Sales Agreement with B. Riley Securities, Inc. and Craig-Hallum Capital Group LLC valued at aggregate offering price of up to $100,000,000 (effective 2025-11-28).
“On November 28, 2025, Actuate Therapeutics, Inc. (the “Company”) entered into an At the Market Issuance Sales Agreement (the “Agreement”) with B. Riley Securities, Inc. and Craig-Hallum Capital Group LLC (each a “Sales Agent” and collectively the “Sales Agents”) under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, $0.000001 par value per share (“Common Stock”), to or through the Sales Agents, as its agents, having an aggregate offering price of up to $100,000,000.”
Les Kreis, Jr. resigned as Director at ACTUATE THERAPEUTICS, INC..
“Les Kreis, Jr. resigned from the Board effective immediately prior to the closing of the Company’s initial public offering.”
Amy Ronneberg was appointed as Director at ACTUATE THERAPEUTICS, INC..
“each of Jason Keyes, Roger Sawhney, and Amy Ronneberg were appointed to the Company’s Board of Directors (the “Board”) on May 20, 2024.”
Roger Sawhney was appointed as Director at ACTUATE THERAPEUTICS, INC..
“each of Jason Keyes, Roger Sawhney, and Amy Ronneberg were appointed to the Company’s Board of Directors (the “Board”) on May 20, 2024.”
Jason Keyes was appointed as Director at ACTUATE THERAPEUTICS, INC..
“each of Jason Keyes, Roger Sawhney, and Amy Ronneberg were appointed to the Company’s Board of Directors (the “Board”) on May 20, 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.